{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:02:12Z","timestamp":1790848932800,"version":"4.1.0"},"reference-count":20,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Cardiol Young"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S1047951126123889_as1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Noonan syndrome is an autosomal dominant RASopathy caused by germline gain-of-function variants in the renin-angiotensin system\/mitogen-activated protein kinase signalling pathway. Hypertrophic obstructive cardiomyopathy is a serious and potentially fatal manifestation of Noonan syndrome, most characteristically associated with RAF1 and RIT1 variants. Trametinib, a selective MEK1\/2 inhibitor, has demonstrated efficacy in Noonan syndrome-associated hypertrophic obstructive cardiomyopathy across several genotypes; however, real-world data pairing distinct genotypes with clinical response\u2014particularly for PTPN11- and RAF1-related disease in older children with prior surgical intervention\u2014remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1047951126123889_as2\">\n                    <jats:title>Cases:<\/jats:title>\n                    <jats:p>We report two 10-year-old males with genetically confirmed Noonan syndrome and severe hypertrophic obstructive cardiomyopathy refractory to conventional pharmacological management, both with prior surgical right ventricular outflow tract intervention. Case 1 carries a PTPN11 c.1528C&gt;G; p. Gln510Glu variant; Case 2 carries a RAF1 c.770C&gt;T; p. Ser257Leu variant, a well-characterised pathogenic variant strongly associated with Noonan syndrome-related hypertrophic obstructive cardiomyopathy. Trametinib was initiated as off-label therapy in both cases, producing rapid, significant reduction of left ventricular outflow tract gradients. Trametinib was well tolerated in Case 1, while Case 2 experienced mild cutaneous pruritus that resolved with antihistamine therapy without requiring dose modification. With continued therapy over subsequent months, both patients demonstrated further incremental haemodynamic improvement together with structural regression of ventricular wall thickness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1047951126123889_as3\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These cases provide complementary evidence supporting the efficacy and tolerability of trametinib, including its rapid response time, across two distinct Noonan syndrome genotypes in older paediatric patients with established, surgically treated hypertrophic obstructive cardiomyopathy. Our findings support mitogen-activated protein kinase kinase inhibition as a genotype-agnostic targeted therapeutic strategy in Noonan syndrome-associated hypertrophic obstructive cardiomyopathy and reinforce the need for prospective trials to standardise protocols and define long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s1047951126123889","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:53:25Z","timestamp":1790848405000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Rapid haemodynamic improvement with trametinib in Noonan syndrome-associated hypertrophic obstructive cardiomyopathy: a report of two cases with distinct genotypes"],"prefix":"10.1017","author":[{"given":"Meena","family":"Al Hadithi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xfzxq83","id-type":"ROR","asserted-by":"publisher"}],"name":"Al Jalila Children\u2019s Speciality Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Elsedawy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xfzxq83","id-type":"ROR","asserted-by":"publisher"}],"name":"Al Jalila Children\u2019s Speciality Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Kasem","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xfzxq83","id-type":"ROR","asserted-by":"publisher"}],"name":"Al Jalila Children\u2019s Speciality Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Alsoufi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xfzxq83","id-type":"ROR","asserted-by":"publisher"}],"name":"Al Jalila Children\u2019s Speciality Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Obeidat","sequence":"additional","affiliation":[{"name":"Al Jalila Children\u2019s Speciality Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-0435","authenticated-orcid":false,"given":"Yakup","family":"Ergul","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xfzxq83","id-type":"ROR","asserted-by":"publisher"}],"name":"Al Jalila Children\u2019s Speciality Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"S1047951126123889_ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.121.003327"},{"key":"S1047951126123889_ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.10537"},{"key":"S1047951126123889_ref7","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2015.114"},{"key":"S1047951126123889_ref18","first-page":"789","article-title":"MEK inhibition for RASopathy-associated hypertrophic cardiomyopathy: clinical application of a basic concept","volume":"40","author":"Chaput","year":"2024","journal-title":"Can J Cardiol"},{"key":"S1047951126123889_ref10","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"S1047951126123889_ref1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3207"},{"key":"S1047951126123889_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61023-X"},{"key":"S1047951126123889_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2010.09.002"},{"key":"S1047951126123889_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.066"},{"key":"S1047951126123889_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2022.05.030"},{"key":"S1047951126123889_ref4","first-page":"37","article-title":"Noonan syndrome","volume":"89","author":"Bhambhani","year":"2014","journal-title":"Am Fam Physician"},{"key":"S1047951126123889_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2024.10.002"},{"key":"S1047951126123889_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ppedcard.2015.01.002"},{"key":"S1047951126123889_ref15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44929"},{"key":"S1047951126123889_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104630"},{"key":"S1047951126123889_ref16","doi-asserted-by":"publisher","DOI":"10.3390\/children11111342"},{"key":"S1047951126123889_ref8","doi-asserted-by":"publisher","DOI":"10.1038\/ng2078"},{"key":"S1047951126123889_ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1475143"},{"key":"S1047951126123889_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0803.2010.00465.x"},{"key":"S1047951126123889_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.04.018"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951126123889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:53:26Z","timestamp":1790848406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951126123889\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":20,"alternative-id":["S1047951126123889"],"URL":"https:\/\/doi.org\/10.1017\/s1047951126123889","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}